| Title | Novel targeted therapies for autoimmunity. | | Author(s) | St Clair EW | | Institution | Department of Medicine, Duke University Medical Center, Box 3874 DUMC, Durham, NC 27710, United States. | | Source | Curr Opin Immunol 2009 Oct 12. | | Abstract | The emergence of new targeted therapies is rapidly improving the treatment of autoimmune disease. These drugs have been variably designed to deplete specific T and B cell subsets, interrupt receptor-ligand interactions, and inhibit the activity of inflammatory mediators relevant to immune function. Abatacept, a co-stimulatory blocker, and rituximab, a B cell depleting antibody, are among the approved therapies seeking new indications, while the newer therapies include Fc receptor-non-binding CD3-specific antibodies, IL-12/23 antibodies, an IL-6 receptor antagonist, a sphingosine-1-phosphate agonist, and small molecule inhibitors of intracellular protein kinases. Antigen-specific therapies are in their infancy, but the latest results administering glutamic acid dehydrogenase peptide to type 1 diabetics are promising. In the future, treatment strategies may increasingly explore the use of drug combinations acting at multiple sites of aberrant immunoregulation to achieve disease quiescence and immune tolerance. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19828300 |
|
